IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio, Inc. (Nasdaq: INAB) has announced the pricing of its initial public offering (IPO) at $10 per share, totaling gross proceeds of $40 million before expenses. The offering consists of 4,000,000 shares and is expected to close on August 3, 2021. Additionally, an underwriter option allows for 600,000 more shares to be purchased. IN8bio specializes in gamma-delta T cell therapies for cancer treatment and is currently conducting Phase 1 trials for its lead candidates targeting glioblastoma and leukemia.